MyelinWatch EL
← Studies & programmes
Myelin repairPreparing for a first study in peopleCurrent status unknown

PRO-1562: a planned study of a possible myelin-repair drug

PRO-1562 · The public study description outlines two steps: first, single doses in healthy adults to assess safety and how much drug reaches the body and cerebrospinal fluid; then monthly doses over six months in adults with relapsing MS and long-term optic-nerve damage.

What is being studied

The public study description outlines two steps: first, single doses in healthy adults to assess safety and how much drug reaches the body and cerebrospinal fluid; then monthly doses over six months in adults with relapsing MS and long-term optic-nerve damage.

Research stage

Preparing for a first study in people

A human study is planned; no current participation route is listed.

What we know so far

The planned study is registered as NCT07826689 / PRO-1562-101. The registry description says it will assess safety and possible effects on myelin and symptoms, but whether it is accepting participants or has started could not be independently confirmed. No results are available.

What this means for patients today

This is a research plan, not an available treatment. It has not been confirmed whether the study is currently accepting participants.

Treatment or approach
PRO-1562 • planned Phase 1/2a MS programme
How it is intended to work
Small-molecule promotion of myelin repair
Where the study is running
Clinical study locations not independently confirmed
Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: Veeva mirror of the trial description (not the primary record) ↗
Published by MyelinWatch
Last substantive MyelinWatch update

Programme updates

  1. Planned Phase 1/2a study

    PRO-1562 registry entry outlines a planned early study

    The ClinicalTrials.gov record NCT07826689 describes a planned two-part study: single doses in healthy adults, followed by monthly doses in adults with relapsing MS and chronic optic neuropathy. The 17 September 2026 posting date and study details were available through a secondary mirror attributing them to ClinicalTrials.gov; they could not be independently checked against the primary record.

    Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: Veeva mirror reporting ClinicalTrials.gov data (secondary source) ↗